Albert Man, Ph.D

Founder, CEO

Dr. Man has over 12 years experience in entrepreneurial stage biotechnology. As a late founder of Prediction Sciences, he was able to bring 2 products from concept to commercialization, and help drive another from concept through preclinical studies. He helped his companies obtain over $20M in non-dilutive small business grant funding. Dr. Man received his PhD in molecular pathology from the University of California San Diego and conducted his graduate research at the Sanford-Burnham Medical Research Institute. He has an additional degree in economics from the University of California Berkeley.

 
 

Paul Kenny, Ph.D

Founder

Dr. Kenny is Ward-Coleman Professor at Mount Sinai Hospital and Chair of the Dorothy H. and Lewis Rosenstiel Department of Pharmacology and Systems Therapeutics. Dr. Kenny also serves as the Director of the Experimental Therapeutics Institute. Among his many research awards, he was the recipient of the prestigious 2010 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Over the last decade, Dr. Kenny has made outstanding contributions to the neuropharmacology and molecular study of drug addiction. Dr. Kenny has published in the highest level scientific journals and is on the editorial boards, or serves as an editor, for leading journals in the field. Dr. Kenny is an elected full member (2009) of the American College of Neuropsychopharmacology (ACNP) and a member of the Board of Scientific Counselors (BSC) for the National Institute on Drug Abuse (NIDA) intramural research program. Dr. Kenny earned his PhD from King’s College London.

 
 

Theodore Kamenecka, Ph.D

Founder

Dr. Kamenecka is an Associate Scientific Director II and associate professor in the Department of Molecular Therapeutics on the Florida campus of The Scripps Research Institute. Dr. Kamenecka has extensive industry experience in drug development, and was a medicinal chemistry at Merck for 6 years before joining Scripps. Dr. Kamenecka has considerable expertise in medicinal chemistry, particularly in design, synthesis and evaluation of novel compounds of biological and therapeutic interest. Coordinating molecular biology, pharmacology, and drug metabolism, Dr. Kamenecka has optimized numerous lead compounds for potency, ADME (absorption, distribution, metabolism, and excretion), safety pharmacology, and toxicology in order to generate compounds suitable for preclinical development. Dr. Kamenecka obtained his Ph.D. at University of California Irvine and performed his post-doc at Memorial Sloan-Kettering Cancer Center.

 
 

George Voren, Ph.D. Candidate

Scientist - In Vivo Pharmacology

Mr. Voren is an expert on brain circuit mechanisms of addiction and in vivo pharmacology. Mr. Voren is also an expert in the design, execution, and analysis of behavioral experiments required for demonstrating efficacy of orexin-1 receptor antagonists in reducing nicotine intake in animal models. Mr. Voren intends to use his experience with Eolas to enter biotechnology entrepreneurship.